PRC2-independent chromatin compaction and transcriptional repression in cancer

Oncogene

Volumn 34, Issue 6, 2015, Pages 741-751

  Vallot, C ^a,b   Herault A ^a,b   Boyle, S ^c   Bickmore, W A ^c,d   Radvanyi, F ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

cancer; chromatin compaction; gene cluster; histone deacetylase inhibitors; polycomb

Indexed keywords

CHROMATIN; EZH2 PROTEIN, HUMAN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLADDER TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYCOMB REPRESSIVE COMPLEX 2; URINARY BLADDER NEOPLASMS;

EID: 84892742949     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.604     Document Type: Article

References (59)

1. Sproul D, Gilbert N, Bickmore WA. The role of chromatin structure in regulating the expression of clustered genes. Nat Rev Genet 2005; 6: 775-781.
2. Pauler FM, Sloane MA, Huang R, Regha K, Koerner MV, Tamir I et al. H3K27me3 forms BLOCs over silent genes and intergenic regions and specifies a histone banding pattern on a mouse autosomal chromosome. Genome Res 2009; 19: 221-233.
3. Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A et al. Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 2007; 1: 286-298.
4. Chambeyron S, Bickmore WA. Chromatin decondensation and nuclear reorganization of the HoxB locus upon induction of transcription. Genes Dev 2004; 18: 1119-1130.
5. Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008; 322: 1717-1720.
6. Simon JA, Kingston RE. Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 2013; 49: 808-824.
7. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell 2008; 32: 232-246.
8. Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell 2010; 38: 452-464.
9. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet 2010; 11: 285-296.
10. Crawley JJ, Furge KA. Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 2002; 3: RESEARCH0075.
11. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006; 38: 1386-1396.
12. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-549.
13. Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 2006; 66: 10664-10670.
14. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS et al. Consolidation of the cancer genome into domains of repressive chromatin by longrange epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010; 12: 235-246.
15. Vallot C, Stransky N, Bernard-Pierrot I, Herault A, Zucman-Rossi J, Chapeaublanc E et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011; 103: 47-60.
16. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955-1959.
17. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
18. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663.
19. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 2012; 338: 1465-1469.
20. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994; 71: 583-594.
21. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
22. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006; 311: 844-847.
23. Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science 2004; 306: 1574-1577.
24. van den Engh G, Sachs R, Trask BJ. Estimating genomic distance from DNA sequence location in cell nuclei by a random walk model. Science 1992; 257: 1410-1412.
25. Gilbert N, Boyle S, Fiegler H, Woodfine K, Carter NP, Bickmore WA. Chromatin architecture of the human genome: gene-rich domains are enriched in open chromatin fibers. Cell 2004; 118: 555-566.
26. Chambeyron S, Da Silva NR, Lawson KA, Bickmore WA. Nuclear re-organisation of the Hoxb complex during mouse embryonic development. Development 2005; 132: 2215-2223.
27. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32: 503-518.
28. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
29. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-164.
30. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
31. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
32. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-273.
33. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005; 11: 8570-8576.
34. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92: 1754-1758.
35. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
36. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2010; 117: 2451-2459.
37. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002; 62: 6456-6461.
38. Lleres D, James J, Swift S, Norman DG, Lamond AI. Quantitative analysis of chromatin compaction in living cells using FLIM-FRET. J Cell Biol 2009; 187: 481-496.
39. Toth KF, Knoch TA, Wachsmuth M, Frank-Stohr M, Stohr M, Bacher CP et al. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J Cell Sci 2004; 117: 4277-4287.
40. Eskeland R, Freyer E, Leeb M, Wutz A, Bickmore WA. Histone acetylation and the maintenance of chromatin compaction by Polycomb repressive complexes. Cold Spring Harb Symp Quant Biol 2011; 75: 71-78.
41. Wen B, Wu H, Shinkai Y, Irizarry RA, Feinberg AP. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet 2009; 41: 246-250.
42. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005; 120: 169-181.
43. Roh TY, Cuddapah S, Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 2005; 19: 542-552.
44. Morey C, Da Silva NR, Perry P, Bickmore WA. Nuclear reorganisation and chromatin decondensation are conserved, but distinct, mechanisms linked to Hox gene activation. Development 2007; 134: 909-919.
45. Soshnikova N, Duboule D. Epigenetic temporal control of mouse Hox genes in vivo. Science 2009; 324: 1320-1323.
46. Sproul D, Nestor C, Culley J, Dickson JH, Dixon JM, Harrison DJ et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci USA 2011; 108: 4364-4369.
47. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-7284.
48. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-22444.
49. Garrick D, De Gobbi M, Samara V, Rugless M, Holland M, Ayyub H et al. The role of the polycomb complex in silencing alpha-globin gene expression in nonerythroid cells. Blood 2008; 112: 3889-3899.
50. Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A. Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis. Genome Biol 2008; 9: R65.
51. Nozawa RS, Nagao K, Igami KT, Shibata S, Shirai N, Nozaki N et al. Human inactive X chromosome is compacted through a PRC2-independent SMCHD1-HBiX1 pathway. Nat Struct Mol Biol 2013.
52. Morey L, Aloia L, Cozzuto L, Benitah SA, Di Croce L. RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells. Cell Rep 2012; 3: 60-69.
53. Wu X, Johansen JV, Helin K. Fbxl10/Kdm2b recruits Polycomb repressive complex 1 to cpg islands and regulates H2A ubiquitylation. Mol Cell 2013; 49: 1134-1146.
54. Tavares L, Dimitrova E, Oxley D, Webster J, Poot R, Demmers J et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 2012; 148: 664-678.
55. Boumber Y, Issa JP. Epigenetics in cancer: what's the future?. Oncology (Williston Park) 2011; 25: 220-226228.
56. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, Van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer 1997; 71: 284-291.
57. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-211.
58. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 7743-7748.
59. Illingworth RS, Botting CH, Grimes GR, Bickmore WA, Eskeland R. PRC1 and PRC2 are not required for targeting of H2A.Z to developmental genes in embryonic stem cells. PLoS One 2012; 7: e34848.